@article{01e04c0e6e1a4fda948690ad36d6253a,
title = "Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2",
abstract = "Tandutinib is a novel inhibitor of tyrosine kinases FLT3, PDGFR and KIT. Our study was to explore the capability of tandutinib to reverse ABC transporter-mediated multidrug resistance. Tandutinib reversed ABCG2-mediated drug resistance in ABCG2-482-R2, ABCG2-482-G2, ABCG2-482-T7 and S1-M1-80 cells and increased the accumulation of doxorubicin, rhodamine 123 and [H3] mitoxantrone in ABCG2-overexpressing cells. Importantly, tandutinib selectively sensitized side population cells to mitoxantrone. Taken together, our results advocate the potency of tandutinib as an ABCG2 modulator and stem-like cells targeted agent to increase efficiency of anticancer drugs.",
keywords = "ABCG2/BCRP, Multidrug resistance, Stem-like cells, Tandutinib, Tyrosine kinase inhibitor",
author = "Zhao, {Xiao Qin} and Dai, {Chun Ling} and Shinobu Ohnuma and Liang, {Yong Ju} and Wen Deng and Chen, {Jun Jiang} and Zeng, {Mu Sheng} and Ambudkar, {Suresh V.} and Chen, {Zhe Sheng} and Fu, {Li Wu}",
note = "Funding Information: This work was supported by the Grants from Chinese National Natural Sciences Foundation Nos. 30672407 and 81072669 (LWF), Chinese Ministry of Education Postdoctor Foundation No. 20100470959 (CLD) and NIH R15 No. 1R15CA143701 (ZSC). We thank Drs S.E. Bates and R.W. Robey (National Cancer Institute, NIH) for the ABCG2 expressing cell line S1-M1-80 and their parental sensitive cell line S1. We thank Gary D. Kruh (Medical Sciences Division, Fox Chase Cancer Center) for murine fibroblasts cell line NIH3T3 and the ABCC4-transfected derivative ABCC4 stable expressing NIH3T3/MRP4-2.",
year = "2013",
doi = "10.1016/j.ejps.2013.04.015",
language = "English",
volume = "49",
pages = "441--450",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",
number = "3",
}